Panbela Therapeutics Inc. PBLA
0.01
0.00
0.00%
as of 24 Sep
- Market cap
- $3.4M
- P/E
- 0.0×
Follow PBLA
| Older periods | Dec '23 | Mar '24 | Jun '24 | Sep '24 | |
|---|---|---|---|---|---|
Current Ratio |
+8 more quarters Free account |
0.25 | 0.17 | 0.05 | 0.26 |
Net Debt/EBITDA |
(0.37) | (0.58) | (0.51) | (0.57) | |
Debt/Assets |
44.01% | 39.84% | 44.55% | 81.15% | |
Debt/Equity |
(1.10) | (1.32) | (0.40) | (0.23) | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.47 | 1.32 | 0.14 | 0.30 | |
Capex/Depreciation |
0.00 | — | 0.00 | 0.00 | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow per Share |
(28.26) | (3.00) | (0.04) | (0.44) | |
Cash per Share |
23.65 | 0.08 | 0.01 | 0.03 | |
Shareholders Equity per Share |
(43.21) | (1.02) | (2.18) | (3.74) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(43.21) | (1.02) | (2.18) | (3.74) | |
Free Cash Flow |
(3.08) | (9.39) | (0.21) | (2.12) | |
Working Capital |
(9.26) | (8.73) | (16.02) | (14.97) | |
Capital Expenditures |
0.00 | — | 0.78 | 0.00 | |
Net Current Asset Value |
(13.45) | (11.93) | (19.21) | (18.17) | |
| Other line items | |||||
Quick Ratio |
0.22 | 0.05 | 0.02 | 0.02 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(28.26) | (3.00) | (0.20) | (0.44) | |
Capex per Share |
0.00 | 0.00 | 0.16 | 0.00 | |
Average Receivables |
0.12 | 0.18 | 0.26 | 0.24 | |
Average Payables |
6.40 | 7.92 | 11.37 | 8.78 | |
Average Assets |
8.39 | 13.50 | 14.48 | 7.90 | |
Average Common Equity |
(6.38) | (0.33) | (2.88) | (10.33) | |
Capex to Sales |
0.00 | — | 0.00 | 0.00 | |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% |
Columns are period end dates